Frontlight ResearchEarly access
Prostate cancer trials in France
93 of 110 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peoplePhase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Bordeaux, Bordeaux Cedex, Caen Cedex 5, Clermont Ferrand Cedex1, Le Mans Cedex 2, Lille, Lyon, Nice Cedex 2, Paris, Strasbourg Cedex 2, Suresnes, Toulouse, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 297 worldwide
- Run by
- Amgen Inc.
See details and how to join2025-520555-89-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 3Not yet taking people in FranceA clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
- Where
- Brest, Clermont-Ferrand, Lille, Lyon, Nice Cedex 2, Nimes Cedex 9, Rennes Cedex, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 265 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-512340-32-01 - Phase 3Taking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Bayonne, Clermont Ferrand Cedex1, Lille, Nîmes, Paris, Rennes Cedex, Strasbourg Cedex 2, Villejuif
- Age
- 18 years and over
- People
- 1,310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - Phase 1/2Taking peopleTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Where
- Creteil Cedex, Lille, Nantes, Paris, Reims, Rennes
- Age
- 18 years and over
- People
- 181 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00 - No phaseTaking peopleClinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
- Where
- Bordeaux, Marseille, Montpellier, Toulouse
- Age
- 18 years and over
- People
- 350
- Run by
- Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT04104529 - Phase 1/2Taking peopleFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
- Where
- Montpellier, Villejuif
- Age
- 18 years and over
- People
- 54 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07332455 - Phase 2Taking peopleA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Bordeaux, Lyon, Marseille, Paris, Villejuif
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00 - Phase 4Not yet taking people in FranceAnalysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
- Where
- Toulouse
- Age
- 70 years and over
- People
- 30
- Run by
- University Hospital, Toulouse
See details and how to joinNCT07766122 · EU 2026-525181-22-00 - Phase 3CompletedDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
- Where
- Nancy
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- ABX advanced biochemical compounds GmbH
See details and how to joinNCT06122584 - Phase 1SuspendedA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Villejuif
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 1Taking peopleA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Lille, Marseille, Nantes, Paris, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 1Not yet taking people in FranceA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Paris, Saint-Herblain
- Age
- 18 years and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - Phase 1Taking peopleA Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- Where
- Lyon, Marseille, Villejuif
- Age
- 18 years and over
- People
- 210 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT05800665 · EU 2023-504013-68-00 - Phase 1Taking peopleA Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Where
- Bordeaux, Lyon, Villejuif
- Age
- 18 years and over
- People
- 355 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06095089 · EU 2023-504063-17-00 - Phase 3Taking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Bordeaux, Brest, Dijon, Lille, Lyon, Paris, Pierre-Bénite, Saint-Herblain Cedex, Strasbourg Cedex 2, Toulouse, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 1,203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - Phase 3Taking peopleA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Bordeaux, Clermont-Ferrand, Lille, Lyon, Nimes Cedex 9, Paris, Rennes Cedex, Villejuif
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00 - Phase 3Active, not recruitingA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Bordeaux, Brest, Clermont Ferrand Cedex1, Le Mans, Lyon, Pierre-Bénite, Reims, Saint-Grégoire, Saint-Herblain Cedex, Strasbourg
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - Phase 3Taking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Caen Cedex 5, Limoges Cedex I, Marseille, Nimes Cedex 9, Paris, Rouen Cedex, Strasbourg Cedex 2, Suresnes, Vandoeuvre Les Nancy_ Cedex
- Age
- 18 years and over
- People
- 1,440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - Phase 1/2Taking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Pierre-Bénite
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - Phase 1/2Taking peopleStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Where
- Pierre-Bénite
- Age
- 18 years and over
- People
- 205 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07288359 - Phase 1Taking peopleA Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Where
- Lille, Lyon
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07244341 · EU 2025-522512-16-00 - Phase 1Not yet taking people in FranceA clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
- Where
- Bordeaux
- Age
- 18 years and over
- People
- 26 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-524080-20-00 - Phase 1/2WithdrawnStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Where
- Lyon, Montpellier, Saint-Herblain, Suresnes, Villejuif
- Age
- 18 years to 130 years
- People
- 283 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00 - Phase 3Taking peopleAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- Where
- Angers, Bordeaux, Bron, Clermont-Ferrand, Paris, Rouen, Saint-Cloud, Saint-Herblain Cedex
- Age
- 18 years to 100 years
- People
- 450 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00